九安医疗(002432) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 reached ¥741,145,950.69, an increase of 60.32% compared to the same period last year[2] - Net profit attributable to shareholders was ¥766,882,199.17, a significant increase of 591.41% year-over-year[2] - Basic earnings per share for Q3 2024 was ¥1.8242, up 674.28% from the same period last year[2] - The company reported a significant increase in investment income, totaling ¥542,894,367.27, which is an 82.94% rise year-over-year[5] - Total operating revenue for the current period is ¥2,092,059,399.68, a decrease of 23.7% from ¥2,745,050,759.03 in the previous period[15] - Net profit for the current period is ¥1,533,576,285.11, an increase of 56.1% compared to ¥983,181,037.09 in the previous period[16] - The total profit for the current period is ¥1,817,131,659.23, up 56.3% from ¥1,163,578,508.98 in the previous period[15] Cash Flow - Operating cash flow net amount for the year-to-date was ¥1,376,895,614.60, reflecting a 100.83% increase compared to the previous year[2] - Cash received from sales of goods and services decreased by 37.86% to ¥1,766,166,160.09 compared to the previous year[5] - The net cash flow from operating activities for Q3 2024 was ¥695,081,093.66, a decrease of 60.3% compared to ¥1,752,388,418.26 in Q3 2023[17] - Cash inflow from financing activities totaled ¥2,747,575,908.37, significantly higher than ¥995,418,132.15 in the same quarter last year[18] - Cash outflow from operating activities totaled ¥1,313,825,364.78, a decrease from ¥1,406,811,532.27 in the same quarter last year[17] Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥24,464,520,263.07, representing an 8.16% increase from the end of the previous year[2] - The total current assets increased to CNY 14,094,178,779.27 from CNY 11,987,605,535.29, representing a growth of approximately 17.6%[12] - The total liabilities increased to CNY 4,442,979,943.80 from CNY 2,794,705,681.74, reflecting a growth of approximately 59.0%[13] - The company's long-term borrowings increased to ¥1,597,000,000.00, a rise of 441.36% from the previous year[5] - The company's total assets increased to CNY 24,464,520,263.07 from CNY 22,619,116,790.11, representing a growth of approximately 8.1%[14] Shareholder Information - The company’s total equity attributable to shareholders was ¥19,272,897,613.90, a slight increase of 0.23% from the end of the previous year[2] - The largest shareholder, Shihezi Sanhe Equity Investment Partnership, holds 23.75% of the shares, totaling 116,544,519 shares[8] - The company has repurchased a total of 29,226,340 shares, accounting for 5.96% of the total share capital, with a total expenditure of RMB 1,179,517,884.38[11] - The second largest shareholder, Bank of China - Huabao CSI Medical ETF, holds 2.71% of the shares, totaling 13,314,773 shares[8] - The company has not disclosed any related party relationships among the top ten shareholders[9] Employee Stock Ownership Plan - The employee stock ownership plan will involve a maximum of 21,700,000 shares, with a purchase price of RMB 20.51 per share[10] - The plan will vest in three phases over 36 months, starting from the approval date of the plan[10] - The company plans to attract and retain core technical talents through the employee stock ownership plan[10] Other Financial Metrics - Cash paid for debt repayment surged by 475.39% to ¥1,131,000,000.00, primarily due to bank loan repayments[6] - Research and development expenses for the current period are ¥177,891,510.59, a decrease of 14.5% from ¥208,123,925.62 in the previous period[15] - The company experienced a tax expense of ¥283,555,374.12, which is an increase of 57.2% compared to ¥180,397,471.89 in the previous period[15] - Other comprehensive income after tax for the current period is -¥141,699,686.58, compared to ¥575,261,274.39 in the previous period[16]